IP Library Granted Patent US 8,133,514
Granted Patent B2
US 8,133,514 · App. 12/473,192 · Granted Mar 13, 2012

Carbon-substituted diketopiperazine delivery systems

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,133,514
App. No.
12/473,192
Granted
Mar 13, 2012
Kind
B2
Abstract

Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and administering these compositions are also provided.

Claims (32)

1. A delivery composition comprising:

(a) an active agent; and

(b) at least one di-C-substituted diketopiperazine of formula I:

wherein R and R 1 are each C 2 -C 24 alkenyl and have at least one functional group selected from the group consisting of O and carboxyl group, and at least one of R and R 1 contain a carboxyl group; and wherein R and R 1 are optionally interrupted by O or N, or a combination thereof.

2. A delivery composition as defined in claim 1 , comprising a microsphere.

3. A delivery composition as defined in claim 2 , wherein said microsphere comprises a microcapsule.

4. A delivery composition as defined in claim 2 , wherein said microsphere has a diameter of less than about 10 μm.

5. A delivery composition as defined in claim 1 , wherein said active agent comprises a fragrance.

6. A delivery composition as defined in claim 1 , wherein said active agent comprises a biologically active agent.

7. A delivery composition as defined in claim 6 , wherein said biologically active agent is selected from the group consisting of a peptide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, or any combination thereof.

8. The delivery composition as defined in claim 7 , wherein said biologically-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, vancomycin, desferrioxamine (DFO), or any combination of any of the foregoing.

9. A delivery composition as defined in claim 6 , wherein said biologically-active agent is selected from the group consisting of an interferon, interleukin-II, insulin, heparin, calcitonin, oxytocin, vasopressin, cromolyn sodium, vancomycin, DFO, or any combination of any of the foregoing.

10. A delivery composition as defined in claim 1 , wherein said diketopiperazine is derived from two α-amino acids.

11. A delivery composition as defined in claim 10 , wherein said two α-amino acids from which said diketopiperazine is derived are independently selected from the group consisting of glutamic acid, aspartic acid, tyrosine, phenylalanine, and optical isomers thereof.

12. A delivery composition as defined in claim 10 , wherein said two α-amino acids from which said diketopiperazine is derived are the same.

13. A delivery composition as defined in claim 10 , wherein said diketopiperazine is prepared by the thermal condensation of said two α-amino acids from which said diketopiperazine is derived.

14. A delivery composition as defined in claim 1 , further comprising (c) at least one enzyme inhibitor.

15. A dosage unit form comprising:

(A) a delivery composition as defined in claim 1 ; and

(B) (a) an excipient,

(b) a diluent,

(c) a disintegrant,

(d) a lubricant,

(e) a plasticizer,

(f) a colorant,

(g) a dosing vehicle, or

(h) any combination thereof.

16. A dosage unit form as defined in claim 15 , comprising an oral dosage unit form.

17. A method for preparing microspheres containing an active agent, said method comprising:

(A) solubilizing, in a solvent, at least one di-C-substituted diketopiperazine according to claim 1 ; and

(B) contacting said diketopiperazine solution with said active agent and a precipitator solution in which said diketopiperazine is insoluble.

18. A method as defined in claim 17 , wherein said diketopiperazine solution has a pH within a first range and said precipitator solution has a pH within a second range, said first range being different than said second range.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2016
From: AVENTISUB LLC
To: MANNKIND CORPORATION
Reel/Frame 040588/0008 →
PATENT SECURITY AGREEMENT Recorded Sep 26, 2014
From: MANNKIND CORPORATION
To: AVENTISUB LLC
Reel/Frame 033831/0110 →
SECURITY AGREEMENT Recorded Jul 3, 2013
From: MANNKIND CORPORATION
To: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
Reel/Frame 030740/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2010
From: MILSTEIN, SAM J.
To: EMISPHERE TECHNOLOGIES, INC.
Reel/Frame 024500/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2010
From: EMISPHERE TECHNOLOGIES, INC.
To: MANNKIND CORPORATION
Reel/Frame 024500/0428 →